Johnson & Johnson

09/27/2024 | Press release | Distributed by Public on 09/27/2024 06:02

TALVEY® (talquetamab tgvs) and DARZALEX FASPRO® (daratumumab and hyaluronidase fihj) based combination shows deep and durable responses in patients with relapsed or refractory[...]